CALGARY, Alberta, May 30, 2025 (GLOBE NEWSWIRE) -- PrairieSky Royalty Ltd. ("PrairieSky" or the "Company") (TSX: PSK) is pleased to announce that the Toronto Stock Exchange (the "TSX") has accepted the notice of PrairieSky's intention to commence a normal course issuer bid (the "NCIB"). On April 14, 2025, PrairieSky announced its intention to seek TSX approval to renew its NCIB for an additional one-year period. The NCIB allows the Company to purchase up to 15,355,946 common shares which represents approxim ...

Company Overview - Spectral AI, Inc. is an artificial intelligence company focused on medical diagnostics, specifically aimed at improving treatment decisions in wound care [3] - The company is developing the DeepView System, a predictive device designed to provide clinicians with an objective assessment of a burn wound's healing potential [3] Leadership Change - Stanley Micek has been appointed as the Chief Operating Officer (COO) of Spectral AI, having previously served as Interim COO since May 2024 [1] - Micek's leadership has been recognized for his operational insight and ability to drive performance, particularly in overseeing the company's Research and Development efforts [1][2] Strategic Focus - The company aims to revolutionize wound care management by utilizing the DeepView System to exceed current standards of care, thereby improving patient outcomes and reducing healthcare costs [3] - Micek expressed enthusiasm about leading the operations team and emphasized the importance of the recent Pivotal Burn Study in driving the company's FDA submission efforts [3]

MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live web ...

Company Overview - VivoPower International PLC is transforming into the world's first XRP-focused digital asset enterprise, focusing on the acquisition, management, and long-term holding of XRP digital assets as part of a diversified digital treasury strategy [2] - The company operates globally, with a presence in the United Kingdom, Australia, North America, Europe, the Middle East, and Southeast Asia, and is recognized as an award-winning global sustainable energy solutions B Corporation [3] Business Units - VivoPower has two main business units: Tembo and Caret Digital. Tembo focuses on electric solutions for customized fleet applications and ancillary services such as financing, charging, battery, and microgrids [3] - Caret Digital is dedicated to maximizing the use cases for renewable power, including digital asset mining [3] Recent Developments - VivoPower announced a US$121 million private placement priced at US$6.05 per share, which is above the last market closing price, as part of its new strategic direction [1]

Core Insights - Adaptive Biotechnologies Corporation announced that its clonoSEQ test for measurable residual disease (MRD) assessment will be featured in 30 presentations at major oncology conferences, including 14 oral presentations [1][2] - The data presented will highlight the clinical actionability of clonoSEQ in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), showcasing its transformative impact on clinical care and drug development [2][3] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [14] - The company aims to leverage its proprietary immune medicine platform to develop clinical diagnostics and therapeutic solutions across various diseases, including cancer and autoimmune disorders [14] Product Information - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in patients with multiple myeloma and B-cell acute lymphoblastic leukemia, and is also available for chronic lymphocytic leukemia [11][12] - The test can detect one cancer cell in one million healthy cells, providing precise monitoring of MRD over time, which informs treatment decisions and predicts patient outcomes [12] Upcoming Presentations - Key presentations at the ASCO Annual Meeting and EHA Congress will include results from several clinical trials demonstrating the efficacy of MRD-guided therapy in multiple myeloma and CLL [6][8] - Notable studies include the MIDAS trial, which involves 718 transplant-eligible newly diagnosed multiple myeloma patients, and the ADVANCE trial with 306 patients, both focusing on MRD status to guide therapy [6][8]

TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Matador Technologies Inc. (“Matador” or the “Company”) (TSXV: MATA, OTCQB: MATAF), a Bitcoin-focused company, announces the closing of a CAD$1.5 million investment from Arrington Capital, a digital asset management firm, as part of its non-brokered private placement offering of units (“Units”) at $0.62 per Unit (the “Offering”). The Offering was announced on May 22, 2025. As part of this first tranche, the Company issued 2,419,354 Units. Each Unit consists of one co ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Links to each presentation are included below. “We were pleased to present three encore presentations yesterday during the CMSC conference. We continue to be impressed by the BRIUMVI data and look forward to co ...

TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Sparton Resources Inc. (SRI: TSX-V) (the “Company”) is pleased to announce that the Company and Eldorado Gold Corporation (“Eldorado”) have closed an agreement, effective May 29, 2025, whereunder Eldorado acquired the Company’s remaining 25% interest in the Bruell Gold Project 51 claim property in Vauquelin township, Quebec. (The Company and Eldorado are referred to jointly herein as “the Parties”.) All dollar figures stated are in Canadian Dollars. The Option Agree ...

Company Overview - Serve Robotics is a leading autonomous sidewalk delivery company focused on developing AI-powered, low-emissions delivery robots aimed at making delivery sustainable and economical [4] - The company was spun off from Uber in 2021 and has completed tens of thousands of deliveries for enterprise partners such as Uber Eats and 7-Eleven [4] - Serve Robotics has scalable multi-year contracts, including an agreement to deploy up to 2,000 delivery robots on the Uber Eats platform across multiple U.S. markets [4] Annual Meeting Details - The Annual Meeting of Stockholders will be held virtually on June 12, 2025, at noon PDT [1] - Stockholders of record as of April 14, 2025, will have the right to participate in the meeting [2] - The company commenced mailing the Notice to stockholders on April 25, 2025, which includes instructions for accessing the Proxy Statement and annual report, as well as voting options [3]

Core Viewpoint - Nexxen International Ltd. has successfully amended its revolving credit facility, reducing the committed facility size and extending the maturity date, which enhances its liquidity for business operations and strategic investments [1][2]. Company Overview - Nexxen is a global advertising technology platform specializing in data and advanced TV, offering a flexible technology stack that includes a demand-side platform (DSP) and supply-side platform (SSP) [3]. - The company is headquartered in Israel and has offices across the United States, Canada, Europe, and Asia-Pacific, and is publicly traded on Nasdaq under the ticker NEXN [4]. Financial Update - The committed facility size of Nexxen's revolving credit facility has been reduced from $90 million to $50 million, with the maturity extended to September 2027 [2]. - The company's strong cash position, combined with the updated credit facility, provides sufficient liquidity to support ongoing business needs and future strategic initiatives [2].